Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series

被引：9

作者：

Roubaud, G. ^{[1
]}

Kind, M. ^{[2
]}

Coindre, J. -M. ^{[3
]}

Maki, R. G. ^{[4
]}

Bui, B. ^{[1
]}

Italiano, A.

机构：

[1] Inst Bergonie, Dept Med Oncol, Bordeaux, France

[2] Inst Bergonie, Dept Radiol, Bordeaux, France

[3] Inst Bergonie, Dept Pathol, Bordeaux, France

[4] Mem Sloan Kettering Canc Ctr, Dept Med & Pediat, Sarcoma Serv, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷 / 03期

关键词：

IMATINIB MESYLATE; KINASE INHIBITOR; MUTANTS; PKC412;

D O I：

10.1093/annonc/mdr631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：804 / +

页数：2

共 13 条

[1]

[Anonymous], J CLIN ONCOL S

[2]

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].

Choi, Haesun ;

Charnsangavej, Chuslip ;

Faria, Silvana C. ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Benjamin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759

[3]

PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib [J].

Corless, CL ;

Schroeder, A ;

Griffith, D ;

Town, A ;

McGreevey, L ;

Harrell, P ;

Shiraga, S ;

Bainbridge, T ;

Morich, J ;

Heinrich, MC .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5357-5364

[4]

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants [J].

Debiec-Rychter, M ;

Cools, J ;

Dumez, H ;

Sciot, R ;

Stul, M ;

Mentens, N ;

Vranckx, H ;

Wasag, B ;

Prenen, H ;

Roesel, J ;

Hagemeijer, A ;

Van Oosterom, A ;

Marynen, P .

GASTROENTEROLOGY, 2005, 128 (02) :270-279

[5]

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation [J].

Dewaele, Barbara ;

Wasag, Bartosz ;

Cools, Jan ;

Sciot, Raf ;

Prenen, Hans ;

Vandenberghe, Peter ;

Wozniak, Agnieszka ;

Schoffski, Patrick ;

Marynen, Peter ;

Debiec-Rychter, Maria .

CLINICAL CANCER RESEARCH, 2008, 14 (18) :5749-5758

[6]

Heinrich M, 2011, J CLIN ONCOL S, V29

[7]

PDGFRA activating mutations in gastrointestinal stromal tumors [J].

Heinrich, MC ;

Corless, CL ;

Duensing, A ;

McGreevey, L ;

Chen, CJ ;

Joseph, N ;

Singer, S ;

Griffith, DJ ;

Haley, A ;

Town, A ;

Demetri, GD ;

Fletcher, CDM ;

Fletcher, JA .

SCIENCE, 2003, 299 (5607) :708-710

[8]

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J].

Heinrich, MC ;

Corless, CL ;

Demetri, GD ;

Blanke, CD ;

von Mehren, M ;

Joensuu, H ;

McGreevey, LS ;

Chen, CJ ;

Van den Abbeele, AD ;

Druker, BJ ;

Kiese, B ;

Eisenberg, B ;

Roberts, PJ ;

Singer, S ;

Fletcher, CDM ;

Silberman, S ;

Dimitrijevic, S ;

Fletcher, JA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4342-4349

[9]

Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor [J].

Huynh, Hung ;

Lee, Jonathan W. J. ;

Chow, Pierce K. H. ;

Ngo, Van Chanh ;

Bin Lew, Guo ;

Lam, Irene W. L. ;

Ong, Hock Soo ;

Chung, Alexander ;

Soo, Khee Chee .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (01) :152-159

[10]

Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. [J].

Kindler, H. L. ;

Campbell, N. P. ;

Wroblewski, K. ;

Maki, R. G. ;

D'Adamo, D. R. ;

Chow, W. A. ;

Gandara, D. R. ;

Antonescu, C. ;

Stadler, W. M. ;

Vokes, E. E. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 →